| 陈文宇.嘉兴地区42例新型冠状病毒肺炎患者临床资料分析[J].浙江中西医结合杂志,2021,31(2): |
| 嘉兴地区42例新型冠状病毒肺炎患者临床资料分析 |
| Analysis of clinical data of 42 patients of 2019 novel coronavirus disease(COVID-19) in Jiaxing area |
| 投稿时间：2020-04-08 修订日期：2020-10-13 |
| DOI： |
| 中文关键词: SARS-CoV-2 COVID-19 嘉兴 临床特征 |
| 英文关键词: |
| 基金项目:2020年嘉兴市抗击新冠肺炎疫情应急科技攻专项(2020GZ30001)；嘉兴市重点学科(呼吸病学)；嘉兴市肺癌精准治疗重点实验室 |
|
| 摘要点击次数: 715 |
| 全文下载次数: 11 |
| 中文摘要: |
| 目的 总结分析嘉兴地区所有2019新型冠状病毒肺炎(COVID-19)的临床特征及诊治情况。方法 回顾分析2019年2月14日至2020年3月4日浙江省嘉兴市所有42例COVID-19患者的临床资料。结果 42例患者中男24例,女18例,年龄在16～72岁,中位年龄为47岁,其中一代病例21例,与一代病例相关的聚集性起病29例,有28例无任何基础疾病；以发热、咳嗽为首发症状的有38例(90.48%)；血液指标中,淋巴细胞计数降低24例(57.1%),嗜酸性粒细胞计数下降25例(59.5%),嗜碱粒细胞计数升高32例(76.2%),CRP上升21例(50%)；有39例(92.9%)患者出现影像学改变,其中两肺多发病变36例(92.3%),胸膜下受累36例(92.3%),有17例(40.5%)患者的出现影像进展,出现进展时间为2～11天,中位天数3.8天,平均(4.59±2.48)天,32例患者影像学出现好转时间为2～26天,中位天数7.5天,平均(8.72±5.33)天；有39例(92.86%)患者选择了含阿比多尔片、达芦那韦考比司他或克立芝的抗病毒方案,有22例(52.4%)联用了莫西沙星片,有20例(47.6%)联用了激素治疗；有17例(40.48%)患者在治疗过程中出现了腹泻、恶心呕吐、皮疹等药物不良反应；有10例(23.8%)进展为重型,其中有6例(60%)进展为危重型；目前有38例(90.5%)好转出院,病毒核酸检测转阴时间为1~32天,中位天数为15.5天,平均(14.41±8.61)天。结论 嘉兴地区的COVID-19患者以一代病例及与一代病例相关的聚集性起病病例为主,临床表现具备COVID-19的一般临床特征,血液指标中嗜酸性粒细胞计数下降和嗜碱粒细胞计数升高值得关注的,大多数患者会出现影像学改变,少数患者病情会迅速进展。缓解临床症状、阻止普通型进展为重型(危重型)、降低出院患者复查核酸检测的复阳率是本地区治疗COVID-19的主要策略。 |
| 英文摘要: |
| SObjectiveSTo summarize and analyze the clinical characteristics, diagnosis, and treatment of all new coronavirus pneumonia (COVID-19) in the Jiaxing area in 2019.SMethodsSRetrospectively analyze all 42 cases of COVID in Jiaxing City, Zhejiang Province, from February 14, 2019, to March 4, 2020. Clinical data of -19 patients.SResultsSAmong the 42 patients, there were 24 males and 18 females, aged 16 to 72 years, with a median age of 47 years, of which 21 cases were one generation, and clustered onset related to one generation 29 There were 28 cases without any underlying disease; 38 cases (90.48%) with fever and cough as the first symptoms; 24 cases (57.1%) of lymphocyte count decreased and 25 cases of eosinophil count decreased in blood index ( 59.5%), basophil counts increased in 32 cases (76.2%), crp increased in 21 cases (50%); imaging changes occurred in 39 patients (92.9%), of which 36 cases had multiple lung lesions (92.3%) ), 36 cases (92.3%) of subpleural involvement, and 17 cases (40.5%) of the patients had image progression, with a progression time of 2 to 11 days, a median of 3.8 days, an average of (4.59 ± 2.48) days, and 32 cases The improvement time of patients" imaging was from 2 to 26 days, with a median of 7.5 days, with an average of (8.72 ± 5.33) days; 39 patients (92.86%) selected abidol-containing tablets and darunavir corbis heOr Kriging"s antiviral program, 22 patients (52.4%) were combined with moxifloxacin tablets, 20 (47.6%) were combined with hormone therapy; 17 (40.48%) patients appeared during the treatment process Adverse drug reactions such as diarrhea, nausea and vomiting, rash; 10 cases (23.8%) progressed to severe, 6 of them (60%) progressed to critically severe; 38 cases (90.5%) improved and were discharged from hospital, viral nucleic acid testing The overcast time ranged from 1 to 32 days, with a median of 15.5 days, with an average of (14.41 ± 8.61) days.SConclusionsSCOVID-19 patients in Jiaxing area are mainly of one generation and clustered onset cases related to one generation. The performance has the general clinical characteristics of COVID-19. The decrease in the eosinophil count, and the increase in basophil count in the blood index are worthy of attention. Most patients will have imaging changes, and a few patients will progress rapidly. Alleviate clinical symptoms Preventing common type from becoming severe (critical) and reducing the rate of rejuvenation of nucleic acid tests for discharged patients are the main strategies for treating COVID-19 in this area. Keywords: SARS-CoV-2; COVID-19; Jiaxing; clinical characteristics; |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
